A global specialty pharmaceutical company focused on chronic endocrine diseases
Dedicated to bringing high quality products to the global endocrine market
Focused on addressing the major unmet clinical and patient needs for patients with chronic endocrine diseases
Innovative research activities focused on circadian-based endocrinology
Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.
Scottish Medicines Consortium (SMC) has today approved the routine use of Alkindi® (hydrocortisone granules in capsules for opening) as the first-line treatment of young children with adrenal insufficiency aged from birth to less than six years of age
Headline data from the Chronocort® pivotal Phase III clinical trial in Europe for adults with congenital adrenal hyperplasia (CAH).
First two patients have been enrolled into the pivotal Phase III clinical trial (“RESTORE”) in the US for adults with congenital adrenal hyperplasia (CAH).
You are leaving http://www.diurnal.co.uk .Links to all outside websites are provided as a resource to our visitors. Outside websites are neither owned or controlled by Diurnal Ltd. Diurnal accepts no responsibility for the content of other websites.×